PER-041-13未知未知
EFFICACY, SAFETY, AND TOLERABILITY OF ORAL CEBRANOPADOL VERSUS MORPHINE SULFATE PR IN SUBJECTS WITH CHRONIC MODERATE TO SEVERE PAIN RELATED TO CANCER.
试验速览
- 阶段
- 未知
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
- 性别
- All
入选标准
- •1. Subjects must have signed an informed consent orm (ICF) indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial.
- •Complementary information is in protocol.
排除标准
- •1. Evidence of ongoing alcohol/drug abuse or history of alcohol/drug abuse within the last 2 years in the investigator’s judgment, based on patient history and physical examination.
- •Complementary information is in protocol.
研究者
相似试验
进行中（未招募）
不适用
CORAL – Cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancerThe trial population, comprising patients with cancer pain requiring WHO Step III analgesics, will represent the typical population suffering from cancer-related pain. Patient having various types of cancer will be included. The pain condition affecting cancer patients represents a mixed type of pain as it is composed of various pain components (i.e., visceral, neuropathic, and somatic) of different dominance depending on the type of cancer, its stage, localization, and previous treatments.MedDRA version: 18.0Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001316-35-NLGrünenthal GmbH655
撤回
3 期
Efficacy, safety, and tolerability of oral cebranopadol versus morphine sulfate PR in subjects with chronic moderate to severe pain related to cancer.Pijn bij kankerpain related to cancerNL-OMON41472Grunenthal25
进行中（未招募）
不适用
CORAL – Cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancerEUCTR2012-001316-35-BEGrünenthal GmbH655
进行中（未招募）
不适用
Clinical Trial comparing the ability of pain reduction and side effects of a new anti-pain medicament Cebranopadol and morphine sulfate Prolonged Release (PR) in patients suffering from chronic cancer pain of moderate to severe strength.EUCTR2012-001316-35-ATGrünenthal GmbH625
进行中（未招募）
1 期
CORAL - Cebranopadol versus morphine prolonged- release in patients with chronic moderate to severe pain related to cancerThe trial population, comprising patients with cancer pain requiring WHO Step III analgesics, will represent the typical population suffering from cancer-related pain. Patient having various types of cancer will be included. The pain condition affecting cancer patients represents a mixed type of pain as it is composed of various pain components (i.e., visceral, neuropathic, and somatic) of different dominance depending on the type of cancer, its stage, localization, and previous treatments.MedDRA version: 18.0Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001316-35-PLGrünenthal GmbH655